Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 8 | 2024 | 127 | 3.220 |
Why?
|
| Fluocinolone Acetonide | 3 | 2024 | 19 | 2.490 |
Why?
|
| Scleritis | 3 | 2022 | 19 | 1.760 |
Why?
|
| Glucocorticoids | 5 | 2024 | 582 | 1.610 |
Why?
|
| Visual Acuity | 5 | 2024 | 326 | 1.560 |
Why?
|
| Drug Implants | 2 | 2024 | 83 | 1.080 |
Why?
|
| Uveitis, Intermediate | 2 | 2023 | 8 | 1.040 |
Why?
|
| Macular Edema | 2 | 2023 | 43 | 0.980 |
Why?
|
| Corneal Ulcer | 2 | 2022 | 16 | 0.980 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2024 | 6 | 0.920 |
Why?
|
| Intravitreal Injections | 1 | 2024 | 56 | 0.900 |
Why?
|
| Tuberculosis, Ocular | 1 | 2024 | 7 | 0.890 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2024 | 32 | 0.870 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2022 | 5 | 0.800 |
Why?
|
| Cataract Extraction | 1 | 2023 | 97 | 0.770 |
Why?
|
| Sarcoidosis | 1 | 2023 | 157 | 0.720 |
Why?
|
| Cataract | 1 | 2023 | 208 | 0.700 |
Why?
|
| Uveitis, Posterior | 1 | 2019 | 12 | 0.620 |
Why?
|
| Multiple Sclerosis | 1 | 2023 | 438 | 0.570 |
Why?
|
| Phacoemulsification | 1 | 2019 | 116 | 0.550 |
Why?
|
| Eyelid Diseases | 1 | 2016 | 18 | 0.500 |
Why?
|
| Conjunctiva | 1 | 2016 | 51 | 0.500 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 1098 | 0.430 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 4896 | 0.380 |
Why?
|
| Retrospective Studies | 8 | 2024 | 14553 | 0.370 |
Why?
|
| Tomography, Optical Coherence | 2 | 2024 | 186 | 0.340 |
Why?
|
| Risk Assessment | 1 | 2019 | 3269 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2024 | 2016 | 0.310 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2481 | 0.280 |
Why?
|
| Humans | 17 | 2024 | 129847 | 0.260 |
Why?
|
| Aged | 6 | 2024 | 22107 | 0.260 |
Why?
|
| Mycophenolic Acid | 2 | 2024 | 110 | 0.250 |
Why?
|
| Methotrexate | 2 | 2024 | 249 | 0.240 |
Why?
|
| Lubricant Eye Drops | 1 | 2024 | 9 | 0.230 |
Why?
|
| Uveomeningoencephalitic Syndrome | 1 | 2024 | 7 | 0.230 |
Why?
|
| Macula Lutea | 1 | 2024 | 21 | 0.230 |
Why?
|
| Conjunctivitis | 1 | 2024 | 30 | 0.220 |
Why?
|
| Ophthalmic Solutions | 1 | 2024 | 75 | 0.220 |
Why?
|
| Endemic Diseases | 1 | 2024 | 31 | 0.220 |
Why?
|
| Granuloma | 1 | 2023 | 90 | 0.200 |
Why?
|
| Polypropylenes | 1 | 2022 | 14 | 0.200 |
Why?
|
| Biological Factors | 1 | 2022 | 36 | 0.200 |
Why?
|
| Immunologic Factors | 1 | 2024 | 229 | 0.200 |
Why?
|
| Female | 9 | 2024 | 68829 | 0.190 |
Why?
|
| Intraocular Pressure | 1 | 2024 | 299 | 0.190 |
Why?
|
| Sutures | 1 | 2022 | 53 | 0.190 |
Why?
|
| Male | 10 | 2024 | 63759 | 0.190 |
Why?
|
| Vitreous Body | 1 | 2022 | 109 | 0.180 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 858 | 0.180 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2024 | 309 | 0.170 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 7066 | 0.170 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2020 | 10 | 0.170 |
Why?
|
| Tattooing | 1 | 2020 | 14 | 0.160 |
Why?
|
| Middle Aged | 6 | 2024 | 31177 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 532 | 0.160 |
Why?
|
| Adult | 7 | 2024 | 35634 | 0.160 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 1951 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 482 | 0.150 |
Why?
|
| Histiocytes | 1 | 2016 | 7 | 0.130 |
Why?
|
| Biopsy | 2 | 2020 | 1089 | 0.130 |
Why?
|
| Registries | 1 | 2023 | 1903 | 0.120 |
Why?
|
| Immunoglobulins | 1 | 2016 | 162 | 0.120 |
Why?
|
| Neck Injuries | 1 | 2015 | 21 | 0.120 |
Why?
|
| Fibrinogen | 1 | 2016 | 164 | 0.120 |
Why?
|
| Complement C3 | 1 | 2016 | 208 | 0.120 |
Why?
|
| Wounds, Penetrating | 1 | 2015 | 63 | 0.110 |
Why?
|
| Computed Tomography Angiography | 1 | 2015 | 115 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 1708 | 0.110 |
Why?
|
| United States | 2 | 2023 | 13913 | 0.110 |
Why?
|
| Respiratory System | 1 | 2015 | 156 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2016 | 377 | 0.110 |
Why?
|
| Colorado | 1 | 2024 | 4410 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2024 | 10241 | 0.100 |
Why?
|
| Young Adult | 3 | 2024 | 12467 | 0.100 |
Why?
|
| Incidence | 1 | 2019 | 2646 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1690 | 0.090 |
Why?
|
| Neutrophils | 1 | 2016 | 1209 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2024 | 10522 | 0.080 |
Why?
|
| Infant | 1 | 2022 | 9018 | 0.070 |
Why?
|
| Child | 2 | 2024 | 20962 | 0.070 |
Why?
|
| Adolescent | 2 | 2024 | 20451 | 0.070 |
Why?
|
| Risk Factors | 1 | 2019 | 9801 | 0.060 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2024 | 70 | 0.050 |
Why?
|
| Retinal Detachment | 1 | 2024 | 58 | 0.050 |
Why?
|
| Fluorescein Angiography | 1 | 2024 | 143 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 85 | 0.050 |
Why?
|
| Reference Standards | 1 | 2022 | 176 | 0.050 |
Why?
|
| Adalimumab | 1 | 2020 | 40 | 0.040 |
Why?
|
| Foreign-Body Reaction | 1 | 2020 | 27 | 0.040 |
Why?
|
| Steroids | 1 | 2020 | 158 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1877 | 0.040 |
Why?
|
| Neck | 1 | 2015 | 95 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1500 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1847 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1617 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 3089 | 0.020 |
Why?
|